RaySearch Laboratories AB (publ) Interim Report January 1 – March 31, 2016

“Revenues from RayStation® increased with 29 percent to SEK 80.8 M (62.8) and prospects are favorable for increased growth for the rest of the year. The development of RayCare® is progressing according to plan and we are planning a public demonstration of the system at the 2016 ASTRO Annual Meeting in Boston at the end of September,” says Johan Löf, President and CEO of RaySearch.

THREE MONTHS (JANUARY-MARCH 2016)

  • Net sales SEK 95.4 M (87.7), of which RayStation SEK 80.8 M (62.7)
  • Profit after tax SEK 17.8 M (25.0), and earnings per share SEK 0.52 (0.73)
  • Operating profit SEK 23.4 M (33.1)
  • Cash flow negative SEK 5.2 M (pos: 7.8)
  • Order intake excluding service agreements SEK 81.9 M (86.3), of which RayStation SEK 72.6 M (69.1)
  • Order backlog for RayStation was SEK 47.1 M (34.3) at the end of the period

SIGNIFICANT EVENTS DURING THE FIRST QUARTER

  • RaySearch released RayStation 5 with support for carbon ion treatment planning, as well as tools and features that represent a totally new approach to treatment planning.
  • RaySearch signed a long-term collaboration agreement with the University of California, San Francisco (UCSF) regarding RayCare.
  • On January 4, 2016, the Class B RaySearch share (RAY B) was transferred from the Small to the Mid Cap segment of Nasdaq Stockholm.
  • In March 2016, 750 Class A shares were converted to Class B shares at the request of a shareholder.

NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

ABOUT RAYSEARCH

RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm, and the company is listed in the Mid Cap segment on Nasdaq Stockholm.

More information about RaySearch is available at www.raysearchlabs.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Tel: +46 8 510 530 00
johan.lof@raysearchlabs.com

Tags:

About Us

RaySearch Laboratories AB (publ) has been pushing the limits of advanced cancer treatment since 2000. Using progressive algorithms, RaySearch develops world leading software used by thousands of the most cutting-edge cancer clinics in the world. The algorithms are based upon founder and CEO Johan Löf’s scientific knowledge, acquired during his PhD on radiation treatment of moving tumors at the Karolinska Institute. The treatment planning system RayStation and the OIS RayCare are the result of extensive development during years of research, and today used to improve chances of survival and quality of life for cancer patients. We fight for a world where cancer is conquered.

Subscribe

Documents & Links